RNA (Ribonucleic Acid)

Subscribe to Selected New Research on RNA

23448 relevant articles (461 outcomes, 1852 trials/studies) found for this Bio-Agent

Description: A polynucleotide consisting essentially of chains with a repeating backbone of phosphate and ribose units to which nitrogenous bases are attached. RNA is unique among biological macromolecules in that it can encode genetic information, serve as an abundant structural component of cells, and also possesses catalytic activity. (Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed)

Also Known As:

Ribonucleic Acid; Gene Products, RNA; Non-Polyadenylated RNA; Acid, Ribonucleic; Non Polyadenylated RNA; RNA Gene Products; RNA, Non Polyadenylated; RNA, Non-Polyadenylated; Ribonucleic acids

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Thornton, Charles A: 5 articles (01/2008 - 12/2004)
2.	Lo, Y M Dennis: 5 articles (02/2007 - 12/2003)
3.	Grünebach, Frank: 5 articles (09/2005 - 02/2003)
4.	Müller, Martin R: 5 articles (09/2005 - 02/2003)
5.	Brossart, Peter: 5 articles (09/2005 - 02/2003)
6.	Chen, Shi-Ming: 4 articles (06/2008 - 01/2006)
7.	Tao, Ze-Zhang: 4 articles (06/2008 - 01/2006)
8.	Xiao, Bo-Kui: 4 articles (06/2008 - 01/2006)
9.	Sullenger, Bruce A: 4 articles (05/2008 - 04/2003)
10.	Green, Todd J: 4 articles (01/2008 - 02/2004)

Related Diseases

1.	Infection 01/01/2003 - "Extremely high agreement was found between the results of ELISA and qualitative detection of HCV-RNA, using a RT-PCR test as a gold standard for the diagnosis of HCV infection. " 02/01/1998 - "The lowest baseline serum HCV RNA concentration was observed in patients with genotype 2 infection and the greatest decrease in HCV RNA from baseline to month 1 in those with genotype 3. The findings suggest that measuring HCV RNA in serum before and soon after beginning treatment can be helpful for selecting patients who are most likely to have a sustained complete response to standard schedule of alpha-IFN and for identifying patients in whom alternative strategies should be examined." 01/01/1985 - "Both subcutaneous and intraperitoneal, but not intravenous administration of fraction I, fraction II, or purified RNA induced significant protection against intraperitoneal infection, the intraperitoneal route of administration being the most effective. " 07/01/2008 - "Taken together, these findings suggest that the Dz molecule can be used as selective and effective inhibitor of HCV RNA replication, which can be explored further for development of a potent therapeutic agent against HCV infection." 05/01/2006 - "These observations significantly broaden the role RNA plays in the cell and suggest that siRNAs could prove to be a potent future therapeutic for the treatment of diseases such as human immunodeficiency virus type 1 (HIV-1) infection. " Order ALL the reference details at left...
2.	Neoplasms (Cancer) 01/01/2008 - "We conclude that electroporation with whole tumor cell RNA and pulsing with UV-irradiated tumor cells are both effective in eliciting antitumor immune response, but RNA electroporation results in more potent tumor vaccination under the examined experimental conditions." 11/01/2003 - "PC3 tumor cells had transiently increased RNA at 12 hours with a marked decrease at 48 hours. " 03/01/1998 - "Northern blot analysis of 14 of the larger tumors showed a marked decrease in the levels of Rb RNA expression. " 12/01/2005 - "Moreover, DAB(389)IL-2-mediated elimination of Tregs followed by vaccination with RNA-transfected DCs significantly improved the stimulation of tumor-specific T cell responses in RCC patients when compared with vaccination alone. " 12/01/2005 - "CONCLUSION: Bolus injection can be considered to be more effective with respect to RNA damage in tumor tissue. " Order ALL the reference details at left...
3.	Chronic Hepatitis C 09/01/2007 - "BACKGROUND: There is a tendency to individualize treatment in chronic hepatitis C patients depending on viral load and rapid clearance of HCV-RNA. " 01/01/2006 - "Prolonged negative HCV-RNA status led to a good outcome in chronic hepatitis C patients with genotype 1b and super-high viral load." 07/01/2005 - "RIB administration preceding combined treatment of RIB with IFN was more effective in Th2 cell expansion than the usual combined treatment of IFN with RIB and led to a relatively early virological clearance in chronic hepatitis C patients with genotype 1b and a high HCV RNA level." 08/01/2000 - "CONCLUSION: The twice-a-day administration of IFN accelerated the clearance of HCV RNA from serum, leading to a more efficient virological response for patients with chronic hepatitis C, but with a high rate of renal toxicity." 01/01/2000 - "Absence of detectable HCV RNA using PCR methodology has become the gold standard of successful treatment of patients with chronic hepatitis C. " Order ALL the reference details at left...
4.	Hepatitis C 07/01/1994 - "This study reveal that IFN therapy for acute hepatitis C may contribute to prevent the progression to chronicity and that the determination of the level of serum HCV RNA, HCV genotypes and anti C 100-3 levels may be useful to predict that efficacy of IFN and also to make a schedule for successful IFN therapy." 01/01/1999 - "In conclusion, the search for HCV RNA by RT-PCR within the liver biopsy specimen can establish rapid and unequivocal diagnosis of hepatitis C in at least 60% of anti-HCV antibody-positive patients who are seronegative for HCV RNA, and thus may help to avoid repeated testing and delayed therapy. " 11/01/2009 - "BACKGROUND: The gold standard for the diagnosis of acute hepatitis C (AHC) is seroconversion to anti-HCV/HCV-RNA positivity, an occurrence frequently missed in clinical practice. " 06/01/2009 - "Quantification of hepatitis C virus (HCV) RNA is essential for the everyday management of chronic hepatitis C therapy. " 07/01/2007 - "The quantification of hepatitis C virus (HCV) RNA is essential for the everyday management of chronic hepatitis C therapy. " Order ALL the reference details at left...
5.	Viremia 09/01/2004 - "On the other hand, the pp67 RNA assay was highly specific and effective in pinpointing high viremia patients. " 08/01/2003 - "Nevertheless, from a viral perspective, the patient most likely to achieve a good outcome following OLT is someone with low-level (< or = 10(9) copies/mL) HCV RNA viremia both pre- and post-OLT and a genotype other than lb. " 01/01/2002 - "RESULTS: A rapid and marked decrease of HCV RNA viremia of more than 2 logs was observed in 10 (71%) of 14 patients at week 2 of treatment. " 08/01/2001 - "HBV/HCV coinfection was associated with lower HBV viremia (8.2 x 10(4) copies/mL) and lower HCV-RNA levels (7 x 10(5) IU/mL), than the corresponding control group (P <.05), with more marked decrease in HBV replication (P <.05). " 06/27/2006 - "DFPP appeared to be effective in reducing HCV viremia and preventing HCV recurrence in patients with high HCV RNA levels after LDLT. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	DNA (Deoxyribonucleic Acid)
2.	Interferons
3.	Interferon-alpha (Interferon Alfa)
4.	Ribavirin (Virazole)
5.	Messenger RNA (mRNA)
6.	Antigens
7.	RNA (Ribonucleic Acid)
8.	Antibodies
9.	Alanine Transaminase (SGPT)
10.	Immunoglobulin M (IgM)

Related Therapies and Procedures

1.	Highly Active Antiretroviral Therapy (HAART)
2.	Drug Therapy (Chemotherapy)
3.	Transplantation (Transplant Recipients)
4.	Transplants (Transplant)
5.	Immunotherapy

Best Treatments:
Research Summary Report
on Infection

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 14726 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>